Differential exoprotease activities confer tumor-specific serum peptidome patterns.
Recent studies have established distinctive serum polypeptide patterns through mass spectrometry (MS) that reportedly correlate with clinically relevant outcomes. Wider acceptance of these signatures as valid biomarkers for disease may follow sequence characterization of the components and elucidati...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1826294414531624960 |
|---|---|
| author | Villanueva, J Shaffer, DR Philip, J Chaparro, C Erdjument-Bromage, H Olshen, AB Fleisher, M Lilja, H Brogi, E Boyd, J Sanchez-Carbayo, M Holland, E Cordon-Cardo, C Scher, H Tempst, P |
| author_facet | Villanueva, J Shaffer, DR Philip, J Chaparro, C Erdjument-Bromage, H Olshen, AB Fleisher, M Lilja, H Brogi, E Boyd, J Sanchez-Carbayo, M Holland, E Cordon-Cardo, C Scher, H Tempst, P |
| author_sort | Villanueva, J |
| collection | OXFORD |
| description | Recent studies have established distinctive serum polypeptide patterns through mass spectrometry (MS) that reportedly correlate with clinically relevant outcomes. Wider acceptance of these signatures as valid biomarkers for disease may follow sequence characterization of the components and elucidation of the mechanisms by which they are generated. Using a highly optimized peptide extraction and matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) MS-based approach, we now show that a limited subset of serum peptides (a signature) provides accurate class discrimination between patients with 3 types of solid tumors and controls without cancer. Targeted sequence identification of 61 signature peptides revealed that they fall into several tight clusters and that most are generated by exopeptidase activities that confer cancer type-specific differences superimposed on the proteolytic events of the ex vivo coagulation and complement degradation pathways. This small but robust set of marker peptides then enabled highly accurate class prediction for an external validation set of prostate cancer samples. In sum, this study provides a direct link between peptide marker profiles of disease and differential protease activity, and the patterns we describe may have clinical utility as surrogate markers for detection and classification of cancer. Our findings also have important implications for future peptide biomarker discovery efforts. |
| first_indexed | 2024-03-07T03:45:16Z |
| format | Journal article |
| id | oxford-uuid:bf408fcc-8e4a-4c7f-94ed-36acc94c0ea0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:45:16Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:bf408fcc-8e4a-4c7f-94ed-36acc94c0ea02022-03-27T05:46:06ZDifferential exoprotease activities confer tumor-specific serum peptidome patterns.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bf408fcc-8e4a-4c7f-94ed-36acc94c0ea0EnglishSymplectic Elements at Oxford2006Villanueva, JShaffer, DRPhilip, JChaparro, CErdjument-Bromage, HOlshen, ABFleisher, MLilja, HBrogi, EBoyd, JSanchez-Carbayo, MHolland, ECordon-Cardo, CScher, HTempst, PRecent studies have established distinctive serum polypeptide patterns through mass spectrometry (MS) that reportedly correlate with clinically relevant outcomes. Wider acceptance of these signatures as valid biomarkers for disease may follow sequence characterization of the components and elucidation of the mechanisms by which they are generated. Using a highly optimized peptide extraction and matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) MS-based approach, we now show that a limited subset of serum peptides (a signature) provides accurate class discrimination between patients with 3 types of solid tumors and controls without cancer. Targeted sequence identification of 61 signature peptides revealed that they fall into several tight clusters and that most are generated by exopeptidase activities that confer cancer type-specific differences superimposed on the proteolytic events of the ex vivo coagulation and complement degradation pathways. This small but robust set of marker peptides then enabled highly accurate class prediction for an external validation set of prostate cancer samples. In sum, this study provides a direct link between peptide marker profiles of disease and differential protease activity, and the patterns we describe may have clinical utility as surrogate markers for detection and classification of cancer. Our findings also have important implications for future peptide biomarker discovery efforts. |
| spellingShingle | Villanueva, J Shaffer, DR Philip, J Chaparro, C Erdjument-Bromage, H Olshen, AB Fleisher, M Lilja, H Brogi, E Boyd, J Sanchez-Carbayo, M Holland, E Cordon-Cardo, C Scher, H Tempst, P Differential exoprotease activities confer tumor-specific serum peptidome patterns. |
| title | Differential exoprotease activities confer tumor-specific serum peptidome patterns. |
| title_full | Differential exoprotease activities confer tumor-specific serum peptidome patterns. |
| title_fullStr | Differential exoprotease activities confer tumor-specific serum peptidome patterns. |
| title_full_unstemmed | Differential exoprotease activities confer tumor-specific serum peptidome patterns. |
| title_short | Differential exoprotease activities confer tumor-specific serum peptidome patterns. |
| title_sort | differential exoprotease activities confer tumor specific serum peptidome patterns |
| work_keys_str_mv | AT villanuevaj differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT shafferdr differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT philipj differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT chaparroc differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT erdjumentbromageh differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT olshenab differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT fleisherm differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT liljah differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT brogie differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT boydj differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT sanchezcarbayom differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT hollande differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT cordoncardoc differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT scherh differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns AT tempstp differentialexoproteaseactivitiesconfertumorspecificserumpeptidomepatterns |